CRL Shareholders' equity
Shareholders' equity at Charles River Laboratories fell to $3.2B in fiscal 2025, from $3.5B in 2024.
Stockholders' equity attributable to the parent, as filed.
SOURCE: us-gaap:StockholdersEquity · EDGAR CompanyFacts · CIK 1100682 · EDGAR ↗ · FY2021–FY2025 · ANNUAL
FY2025$3.2B
FY2024 $3.5B
HIGH$3.6B FY2023
LOW$2.5B FY2021
History AS FILED · DERIVATION SHOWN WHERE DERIVED
| Fiscal year | Shareholders' equity | Change |
|---|---|---|
| FY2025 | $3.2B | $-297M |
| FY2024 | $3.5B | $-135M |
| FY2023 | $3.6B | +$621M |
| FY2022 | $3.0B | +$442M |
| FY2021 | $2.5B | — |
More SAME DATA, OTHER VIEWS
Shareholders' equity across coverage → · CRL company view →
Revenue · Net income · Operating cash flow · Free cash flow · Capital expenditure · Cash & equivalents · Total assets · Total debt · Return on equity · Days sales outstanding
Not investment advice. Every figure on this page is an XBRL fact from the issuer's own SEC filings or an arithmetic over such facts with the method shown. No forecast is made; no posture is expressed.